Clinical Trial

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies the effect of isatuximab, carfilzomib, and pomalidomide in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Isatuximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as pomalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving isatuximab, carfilzomib, and pomalidomide may help treat patients with multiple myeloma.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2021-04-14; most recent amendment 2026-06-30.
Status change: Recruiting → Active, Not Recruiting 2023-12-07
Status change: Not Yet Recruiting → Recruiting 2022-05-27
Trial Details
NCT Number NCT04850599
Lead Sponsor OHSU Knight Cancer Institute
Collaborators: Oregon Health and Science University, Sanofi
Conditions Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Enrollment 5 participants
Start Date 2022-06-14
Primary Completion 2027-10-15 (estimated)
Study Completion 2029-02-21 (estimated)
Updated on ClinicalTrials.gov 2026-07-02